• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Asembia AXS25: Cell and Gene Therapies Enter New Phase of Growth in Specialty Pharmacy

by MM360 Staff | Apr 30, 2025 | Myeloma News

Source: Pharmacy Times articles As the cell and gene therapy pipeline expands, experts at Asembia’s AXS25 Summit emphasized the need for error-proof logistics, value-based access strategies, and coordinated reimbursement models. Read More

Asembia AXS25: Pharmacists Continue to Expand Clinical, Collaborative Role in Health Care

by MM360 Staff | Apr 30, 2025 | Myeloma News

Source: Pharmacy Times articles At Asembia’s AXS25 Summit, Shea Hudson spotlighted how pharmacists are transforming into essential clinical partners through advanced technology, patient advocacy, and value-based collaboration. Read More

Asembia AXS25: Navigating Challenges in Cell and Gene Therapy

by MM360 Staff | Apr 29, 2025 | Myeloma News

Source: Pharmacy Times articles Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies. Read More

Targeted Therapies Transform CLL Care: Inside the Era of BTK and BCL-2 Inhibitors

by MM360 Staff | Apr 29, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Asembia AXS25: Pharmacy Perspectives on the Inflation Reduction Act

by MM360 Staff | Apr 29, 2025 | Myeloma News

Source: Pharmacy Times articles Experts share operational challenges and patient care implications of the Inflation Reduction Act’s (IRA) drug pricing reforms. Read More

AACR 2025: Orally Bioavailable RIPTAC Therapeutic Targets p53-Y220C Mutant Tumors for Selective Cancer Cell Death

by MM360 Staff | Apr 29, 2025 | Myeloma News

Source: Pharmacy Times articles A novel orally bioavailable RIPTAC therapeutic targeting the p53-Y220C mutation demonstrates selective cancer cell killing by inducing proximity between mutant p53 and an essential protein, offering a promising new strategy for treating...
« Older Entries

Recent Content

  • Asembia AXS25: Cell and Gene Therapies Enter New Phase of Growth in Specialty Pharmacy
  • Asembia AXS25: Pharmacists Continue to Expand Clinical, Collaborative Role in Health Care
  • Asembia AXS25: Navigating Challenges in Cell and Gene Therapy
  • Targeted Therapies Transform CLL Care: Inside the Era of BTK and BCL-2 Inhibitors
  • Asembia AXS25: Pharmacy Perspectives on the Inflation Reduction Act
  • An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC
  • AACR 2025: Orally Bioavailable RIPTAC Therapeutic Targets p53-Y220C Mutant Tumors for Selective Cancer Cell Death
  • Investigating the Addition of Surgery to ICI Therapy in Kidney Cancer
  • Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
  • TAR-200 Shows High Response Rates in Bladder Cancer Subset
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT